{"id":24211,"date":"2019-08-20T00:00:00","date_gmt":"2019-08-20T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2019\/08\/20\/uspstf-recommends-genetic-counseling-for-high-brca-risk\/"},"modified":"2019-08-21T16:06:56","modified_gmt":"2019-08-21T16:06:56","slug":"uspstf-recommends-genetic-counseling-for-high-brca-risk","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2019\/08\/20\/uspstf-recommends-genetic-counseling-for-high-brca-risk\/","title":{"rendered":"USPSTF Recommends Genetic Counseling for High <i>BRCA<\/i> Risk"},"content":{"rendered":"<h3>But counseling not recommended for women without personal, family history, ancestry associated with <i>BRCA<\/i> mutations<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>TUESDAY, Aug. 20, 2019 (HealthDay News) &#8212; The U.S. Preventive Services Task Force (USPSTF) recommends that women who are at increased risk for <i>BRCA1\/2<\/i> mutations should undergo genetic counseling, and if indicated, genetic testing. These recommendations form the basis of a final recommendation statement published in the Aug. 20 issue of the <i>Journal of the American Medical Association<\/i>.<\/p>\n<p>Heidi D. Nelson, M.D., M.P.H., from Oregon Health &#038; Science University in Portland, and colleagues updated the 2013 USPSTF review on the benefits and harms of risk assessment, genetic counseling, and genetic testing for <i>BRCA1\/2<\/i>-related cancer in women.<\/p>\n<p>The task force found adequate evidence that the benefits of risk assessment, genetic counseling, genetic testing, and interventions were moderate for women with a family or personal history or ancestry associated with an elevated risk for harmful <i>BRCA1\/2<\/i> gene mutations. Adequate evidence was found that these benefits are small to none for women whose personal or family history or ancestry is not associated with an increased risk for <i>BRCA1\/2<\/i> mutations. Based on these findings, the USPSTF recommends an appropriate brief familial risk assessment tool for women with relevant personal or family history or ancestry. Women with a positive result should receive genetic counseling, and if indicated, genetic testing (B recommendation). Routine risk assessment, genetic counseling, and genetic testing are not recommended for women without a personal or family history or ancestry associated with <i>BRCA<\/i> mutations (D recommendation).<\/p>\n<p>&#8220;Some women can benefit from risk assessment, counseling, and testing, but not all women need these services,&#8221; task force chair Douglas K. Owens, M.D., said in a statement.<\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2748515\" target=\"_new\" rel=\"noopener noreferrer\">Recommendation Statement<\/a><\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2748514\" target=\"_new\" rel=\"noopener noreferrer\">Evidence Report<\/a><\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/2748486\" target=\"_new\" rel=\"noopener noreferrer\">Editorial 1 (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamasurgery\/article-abstract\/2748637\" target=\"_new\" rel=\"noopener noreferrer\">Editorial 2 (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2748329\" target=\"_new\" rel=\"noopener noreferrer\">Editorial 3 (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2748668\" target=\"_new\" rel=\"noopener noreferrer\">Editorial 4 (subscription or payment may be required)<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2019 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>But counseling not recommended for women without personal, family history, ancestry associated with <i>BRCA<\/i> mutations<\/p>\n","protected":false},"author":6,"featured_media":24227,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-24211","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/24211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=24211"}],"version-history":[{"count":0,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/24211\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/24227"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=24211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=24211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=24211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}